Humacyte, Inc. (NASDAQ:HUMA) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Humacyte, Inc. (NASDAQ:HUMA) have been given a consensus recommendation of “Buy” by the seven analysts that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $11.00.

Several research firms recently issued reports on HUMA. EF Hutton Acquisition Co. I upgraded shares of Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. Cantor Fitzgerald reiterated an “overweight” rating and set a $13.00 price target on shares of Humacyte in a research report on Friday, September 20th. Piper Sandler set a $6.00 price target on shares of Humacyte and gave the company a “neutral” rating in a research report on Friday, October 18th. BTIG Research reiterated a “buy” rating and set a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. Finally, TD Cowen reiterated a “buy” rating and set a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th.

Insider Activity

In other news, Director Brady W. Dougan sold 352,112 shares of the firm’s stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $6.35, for a total value of $2,235,911.20. Following the completion of the transaction, the director now owns 3,677,262 shares of the company’s stock, valued at approximately $23,350,613.70. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, Director Brady W. Dougan sold 252,676 shares of Humacyte stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $6.71, for a total value of $1,695,455.96. Following the completion of the transaction, the director now owns 4,306,464 shares in the company, valued at $28,896,373.44. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Brady W. Dougan sold 352,112 shares of Humacyte stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $6.35, for a total transaction of $2,235,911.20. Following the completion of the transaction, the director now owns 3,677,262 shares of the company’s stock, valued at $23,350,613.70. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,084,153 shares of company stock valued at $6,869,996. 11.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in HUMA. nVerses Capital LLC purchased a new position in Humacyte in the second quarter worth approximately $28,000. Hartline Investment Corp purchased a new position in Humacyte in the first quarter worth approximately $70,000. Concurrent Investment Advisors LLC purchased a new position in Humacyte in the third quarter worth approximately $75,000. Principal Financial Group Inc. purchased a new position in Humacyte in the second quarter worth approximately $83,000. Finally, Profund Advisors LLC purchased a new position in Humacyte in the second quarter worth approximately $97,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Humacyte Price Performance

Humacyte stock opened at $5.22 on Wednesday. Humacyte has a 12-month low of $2.08 and a 12-month high of $9.97. The stock has a market cap of $623.01 million, a P/E ratio of -4.14 and a beta of 1.47. The company has a 50-day moving average price of $5.51 and a 200 day moving average price of $6.12. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.61.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Sell-side analysts anticipate that Humacyte will post -1.09 earnings per share for the current year.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.